… At our offices in Leiden we are advancing our proprietary Axiomer RNA-editing platform technology. Our ProQRians, … USA. ProQR is focused on advancing its proprietary Axiomer™ RNA-editing platform technology to develop life …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi
… targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to … for cardiovascular diseases, and progress made across the Axiomer platform €89.4 million cash and cash equivalents as …
… transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the … perspective in guiding the Company in the translation of Axiomer, our leading RNA editing platform technology, to the …
… Cardiovascular Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues … with successful defense of opposition against a key Axiomer patent protecting ADAR-mediated RNA editing … against our strategy to accelerate the development of Axiomer,” said Daniel A. de Boer, Chief Executive Officer of …
… strategy to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across … RNA editing technology – Accelerate development of the Axiomer ® RNA base-editing technology platform, including an … The Company will accelerate the development of its Axiomer ® RNA editing platform and pipeline activities and …
… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … webcast will be available for approximately 30 days. About Axiomer ® ProQR is pioneering a next-generation RNA base …
